Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00225927
Other study ID # 2
Secondary ID
Status Completed
Phase N/A
First received September 16, 2005
Last updated February 28, 2011
Start date June 2004
Est. completion date June 2010

Study information

Verified date March 2010
Source McMaster University
Contact n/a
Is FDA regulated No
Health authority Canada: Canadian Nuclear Safety CommissionCanada: Ministry of Health & Long Term Care, Ontario
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a new surgical technique (radioguided seed localization) for localizing nonpalpable breast tumours is better than the standard technique (needle localization).


Description:

Most breast cancers are removed by partial mastectomy/lumpectomy. The most important factor in ensuring that the cancer does not return in the breast is to ensure that it is completely removed during surgery. Complete removal is dependent on having a rim of normal tissue (clear margin) surrounding the cancer. If the margin is positive, or the cancer recurs, more surgery or mastectomy is required. Approximately one third of breast cancers are detected by mammograms or ultrasounds and cannot be felt by patients or physicians. Accordingly, a localization technique is required to help the surgeon to find and remove the cancer. The current technique (needle localization) has a higher chance of having cancer cells at the margin. This is a study about a surgical technique. The objective of this comparison study is to determine whether a new technique (radioguided seed localization) is a better way to remove nonpalpable breast cancers. The main objective of this study is to determine if the new technique generates fewer positive margins compared to the standard technique. An improved technique would benefit thousands of women every year.


Recruitment information / eligibility

Status Completed
Enrollment 333
Est. completion date June 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed invasive or in situ breast carcinoma

- Nonpalpable breast tumour

- Candidate for breast conserving surgery (BCS) based on clinical and radiologic evaluation

Exclusion Criteria:

- Histological confirmation more than 3 months from enrollment

- Pregnancy or lactation

- Contraindication to BCS or patient requests mastectomy

- Age less than 18 years

- Male patient

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
radioguided seed localization for nonpalpable breast cancers
radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery

Locations

Country Name City State
Canada Juravinski Cancer Centre Hamilton Ontario
Canada St. Joseph's Healthcare Hamilton Ontario
Canada Princess Margaret Hospital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
McMaster University Canadian Breast Cancer Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the number of positive margins following excision of the nonpalpable breast tumours for the two different surgical techniques immediate post-operative pathology results No
Secondary Compare procedure times, complications and volume of tissue excised for both techniques intra-operative No
See also
  Status Clinical Trial Phase
Completed NCT02794064 - A Prototype Tri-modal Imaging Device for Breast Cancer Phase 1
Recruiting NCT01630226 - Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Phase 2
Completed NCT02005887 - TRial on the Endocrine Activity of Neoadjuvant Degarelix Phase 2
Terminated NCT01598285 - A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer